Angry investors let ‘er rip at Dendreon (DNDN) leadership at the Provenge-maker’s annual meeting on Wednesday. And with good reason: stock price decreased 82 percent over the last year. “The long-term future for Provenge is bright,” countered CEO John Johnson, explaining the potential for a partner to help market the drug in Europe. The same day, shares soared after Summer Street initiated the stock with a buy rating. But let’s not get too excited here – Provenge still has JNJ’s Zytiga and Medivation’s up-and-coming enzalutamide to contend with.
EMRs + mergers = busy hospital CIOs. Increasing hospital M&A activity, which requires merging dozens of billing and procurement systems, combined with hospitals’ move to digital health records, can make things pretty complicated, as this WSJ column points out.
CellScope, a Rock Health startup with a device that connects to the iPhone with the intention of enabling remote diagnosis of ear infection, raised $1 million this week.
The Healthcare Payments Industry Has a Perception Problem
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
As the result of a five-year, $173 million NIH initiative called the Human Microbiome Project, scientists produced the first comprehensive genetic map of the microbes that live in a healthy body. A better understanding of bacteria and organisms in the body could lead to new advances in the diagnosis and treatment of disease.